% | $
Quotes you view appear here for quick access.

Amgen Inc. Message Board

  • breadwinna2000 breadwinna2000 Nov 1, 2012 11:35 PM Flag

    AMBS 2 cents now 5 cents soon, and then the fun begins. No limits on this one. snooze if you want

    $AMBS what a monster broke 2 cents today closed with a gain of 158%! Hands showed how strong they were, as MM's tried to slow it down before 1 cent after it broke 1 cent and all day today, yet it closed at nearly the high of the day. This is not a make believe stock here. HUGE potential. Was under the radar, but not now, the buzz is getting crazy.
    8K OUT / AMGEN co'founder buying 1M shares at 0.01 take a look at the chart 1O CENTS POSSIBLE, i'll take 5 cents though... lol. I have seen and alerted stocks which run 1,000% to 70,000% and this has all the ingredients. I am not saying it will, but just look at the chart the last 2 days; as soon as it was revealed that AMGEN co founder bought shares, LOOK how STRONG it has been, and how fast it has moved, you cant IGNORE.
    This stock has NO LIMIT now. 1 call from the big boys and BINGO

    I found this from another trader written a month ago... BEFORE all this increedible new news....
    nice read.

    "AMBS .008 cent Hot Biotech Stock- DRUG is FUNDED by MICHAEL J. FOX FOUNDATION for PARKINSON'S DISEASE. AMBS Released 2 Positive Drug Studies/Results and the stock is Poised to Run High!

    AMBS - Only Biotech Stock with a "Potential Cure for Parkinson's Disease." This Stock is Way Undervalued. AMBS has only 108 mm shares Outstanding (float is around 40mm). The market cap is only $1 mm and there's already been over $30mm invested in the research & development of AMBS product candidates from biopharmaceutical companies, non-profit organizations, academic researchers and government agencies, including the National Institutes of Health.

    AMBS - Just announced a new Positive Study for its proprietary anti-apoptotic therapeutic protein known as MANF. According to a 2011 report by Visiongain, the market for Parkinson's disease drugs could grow to a value of $3.75 billion by 2015; AMBS is working on a candidate in the disease-modifying drug class which, if successful, could grab significant market share as well as substantially grow the overall Parkinsons drug market. There are currently no diagnostic tests available for Parkinsons disease, thus making AMBS test a first of its kind product capable of gaining a market leading position.

    AMBS - Owns the rights to a potential Cure for Parkinson's Disease. This news & study out today tells us 3 very important things: 1. The study describes the critical role that MANF plays in protecting the Neuron's affected by Parkinson's Disease. 2. The study clearly shows that when MANF is removed from the Genome severe degeneration of the Neuron's occurs. 3. The study clearly shows that MANF plays a critical role in Membrane trafficking and Metabolic changes in the Neuron's affected by Parkinson's Disease.

    4 Reasons Why AMBS - is the Hottest Undiscovered Biotech Stock play right now...

    1. AMBS has a Parkinsons disease program, comprised of an early detection diagnostic blood test and a disease-modifying protein drug candidate. AMBS owns the rights to a potential cure for Parkinsonsa promising therapeutic protein known as MANF that prevents a type of cell death called apoptosis. That program is currently funded by a research grant from the Michael J. Fox Foundation for Parkinsons research...

    2. AMBS also owns the license to a groundbreaking diagnostic platform called NuroPro for Parkinsons that allows neurologists to accurately diagnose and track the progression of Parkinsons disease in patients. The Companies believe that Amarantus NuroPro test for Parkinsons disease could be on market in certain regions as early as 2013.

    3. Over $30million has already been invested in the research and development of AMBS product candidates from biopharmaceutical companies, non-profit organizations, academic researchers and government agencies, including the National Institutes of Health.

    4. AMBS announced Drug Test Results & the publication of positive, peer-reviewed efficacy data for MANF in an animal model of myocardial infarction. The results were published in The Journal of Biological Chemistry (JBC) by the Glembotski Lab at the San Diego State University's (SDSU) Department of Biology and the SDSU Heart Institute. The research paper entitled "Mesencephalic astrocyte-derived neurotrophic factor (MANF) protects the heart from Ischemic damage and is selectively secreted upon ER calcium depletion" reports a ~44% reduction in infarct zone size in MANF-treated mice when compared with controls.! "

    Sentiment: Strong Buy

158.30-2.26(-1.41%)Apr 29 4:00 PMEDT